We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

143 hedge funds and large institutions have $1.47B invested in Epizyme, Inc in 2020 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

888% more call options, than puts

Call options by funds: $47.9M | Put options by funds: $4.84M

41% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 22

11% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 47

5% more funds holding

Funds holding: 136143 (+7)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

35% less capital invested

Capital invested by funds: $2.25B → $1.47B (-$781M)

Holders
143
Holders Change
+7
Holders Change %
+5.15%
% of All Funds
3.15%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
31
Increased
52
Reduced
47
Closed
22
Calls
$47.9M
Puts
$4.84M
Net Calls
+$43M
Net Calls Change
-$33.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Principal Financial Group
76
Principal Financial Group
Iowa
$764K -$180K -8,398 -15%
WC
77
Woodstock Corp
Massachusetts
$746K
AIG
78
American International Group
New York
$713K -$57K -2,656 -5%
TD Asset Management
79
TD Asset Management
Ontario, Canada
$704K +$277K +12,900 +40%
Legal & General Group
80
Legal & General Group
United Kingdom
$681K +$507K +23,604 +116%
Voloridge Investment Management
81
Voloridge Investment Management
Florida
$681K +$943K +43,923 New
Wells Fargo
82
Wells Fargo
California
$654K +$5.8K +270 +0.6%
Citadel Advisors
83
Citadel Advisors
Florida
$634K +$355K +16,520 +68%
MWNA
84
Marshall Wace North America
New York
$619K +$857K +39,912 New
Marshall Wace
85
Marshall Wace
United Kingdom
$593K +$821K +38,239 New
Barclays
86
Barclays
United Kingdom
$553K -$938K -43,665 -55%
CSS
87
Cubist Systematic Strategies
Connecticut
$553K +$34.9K +1,623 +5%
BNP Paribas Financial Markets
88
BNP Paribas Financial Markets
France
$532K +$501K +23,313 +213%
MIM
89
MetLife Investment Management
New Jersey
$502K -$82.4K -3,837 -11%
State Board of Administration of Florida Retirement System
90
State Board of Administration of Florida Retirement System
Florida
$490K +$162K +7,550 +31%
DC
91
Diametric Capital
Massachusetts
$471K +$136K +6,332 +26%
Balyasny Asset Management
92
Balyasny Asset Management
Illinois
$458K +$635K +29,557 New
SEI Investments
93
SEI Investments
Pennsylvania
$440K -$28.7K -1,337 -5%
QIM
94
Quantitative Investment Management
Virginia
$412K +$571K +26,586 New
WMSA
95
Weiss Multi-Strategy Advisers
New York
$389K -$106K -4,923 -16%
AG
96
Algert Global
California
$387K -$434K -20,206 -45%
Man Group
97
Man Group
United Kingdom
$382K +$529K +24,643 New
MLICM
98
Metropolitan Life Insurance Company (MetLife)
New York
$362K -$45.7K -2,128 -8%
Simplex Trading
99
Simplex Trading
Illinois
$350K +$430K +20,023 +782%
SC
100
Slow Capital
California
$333K -$144K -6,707 -24%

EPZM Hedge Fund Activity: Q1 2020 in Review

143 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2020, worth a combined $1.47B — down 35% from $2.25B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EPZM positions and 22 closed out — a net gain of 9 holders — while 52 added to existing stakes and 47 trimmed.

The largest buyer was RP Management, adding an estimated $53.7M. The largest seller was Opaleye Management, exiting entirely with an estimated $34.1M sold.

  • 143 institutional investors held Epizyme, Inc (EPZM) as of Q1 2020, up from 136 in Q4 2019.
  • Funds reported $1.47B of Epizyme, Inc stock for Q1 2020, down 35% quarter-over-quarter.
  • 31 funds opened new Epizyme, Inc positions in Q1 2020 and 22 closed out, a net change of +9 holders.
  • The largest Epizyme, Inc buyer in Q1 2020 was RP Management, an estimated $53.7M added.
  • The largest Epizyme, Inc seller in Q1 2020 was Opaleye Management, an estimated $34.1M sold.

Based on aggregated 13F filings for Q1 2020.